Chengdu Biostar Pharmaceuticals Ltd
-
China Approves Utidelone as Primary New Drug of Epothilone Class for Breast Cancer
China NMPA announced on that Utidelone injection (UTD1), applied by Chengdu Biostar Pharmaceuticals Ltd., has been approved to market on Mar 15th, 2021, which provides a new treatment option for metastatic breast cancer patients.
